[HTML][HTML] Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized …
Y Owada, M Okazaki, T Ikeda, R Yamamoto… - Growth Hormone & IGF …, 2022 - Elsevier
Objective Under clinical development for patients with growth hormone deficiency, JR-142 is
a long-acting growth hormone with a half-life extended by fusion with modified serum …
a long-acting growth hormone with a half-life extended by fusion with modified serum …
Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys
N Ashkenazi, M Rosenstock, H Hallak… - Growth Hormone & IGF …, 2016 - Elsevier
Purpose TV-1106 is a recombinant human albumin genetically fused to growth hormone
which is intended to reduce the frequency of injections for GH therapy users. We report the …
which is intended to reduce the frequency of injections for GH therapy users. We report the …
A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth …
KCJ Yuen, GS Conway, V Popovic… - The Journal of …, 2013 - academic.oup.com
Background: Administration of daily recombinant human GH (rhGH) poses a considerable
challenge to patient compliance. Reduced dosing frequency may improve treatment …
challenge to patient compliance. Reduced dosing frequency may improve treatment …
Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV‐1106, a Long‐Acting Growth Hormone, in Healthy Japanese and …
O Cohen‐Barak, H Barkay… - Clinical …, 2017 - Wiley Online Library
TV‐1106 is a human serum albumin genetically fused to recombinant human growth
hormone, designed to provide a long‐acting alternative to daily growth hormone (GH) …
hormone, designed to provide a long‐acting alternative to daily growth hormone (GH) …
Pharmacokinetics, Pharmacodynamics, and Safety of a Long‐Acting Human Growth Hormone (MOD‐4023) in Healthy Japanese and Caucasian Adults
WG Kramer, M Jaron‐Mendelson… - Clinical …, 2018 - Wiley Online Library
Daily injections of growth hormone (GH) as replacement therapy in GH‐deficient (GHD)
patients may cause poor compliance and inconvenience. C‐terminal peptide–modified …
patients may cause poor compliance and inconvenience. C‐terminal peptide–modified …
MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults
CJ Strasburger, P Vanuga, J Payer… - European Journal of …, 2017 - academic.oup.com
Objective Growth hormone (GH) replacement therapy currently requires daily injections,
which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth …
which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth …
Development of a sustained-release recombinant human growth hormone formulation
Recombinant human growth hormone (rhGH) therapy for short stature must be administered
as a daily injection because of its poor bioavailability and short half-life. In the present study …
as a daily injection because of its poor bioavailability and short half-life. In the present study …
In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone
O Hershkovitz, A Bar-Ilan, R Guy… - Molecular …, 2016 - ACS Publications
MOD-4023 is a novel long-acting version of human growth hormone (hGH), containing the
carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG). MOD-4023 is …
carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG). MOD-4023 is …
Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze …
B Liedert, U Forssmann, P Wolna, M Golob… - BMC Clinical …, 2010 - Springer
Background Somatropin is recombinant human growth hormone (GH) used for the treatment
of growth failure in children and GH deficiency in adults. Two concentrations of a liquid …
of growth failure in children and GH deficiency in adults. Two concentrations of a liquid …
Comparative Pharmacokinetics and Pharmacodynamics of a New Sustained-Release Growth Hormone (GH), LB03002, Versus Daily GH in Adults with GH …
Context: LB03002 is a novel sustained-release GH preparation administered once weekly.
Objective: Our objective was to examine the pharmacokinetics, pharmacodynamics, and …
Objective: Our objective was to examine the pharmacokinetics, pharmacodynamics, and …